CR20200581A - Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos - Google Patents
Compuestos inhibidores de rip1 y métodos para preparar y usar los mismosInfo
- Publication number
- CR20200581A CR20200581A CR20200581A CR20200581A CR20200581A CR 20200581 A CR20200581 A CR 20200581A CR 20200581 A CR20200581 A CR 20200581A CR 20200581 A CR20200581 A CR 20200581A CR 20200581 A CR20200581 A CR 20200581A
- Authority
- CR
- Costa Rica
- Prior art keywords
- making
- methods
- rip1
- same
- inhibitory compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
En la presente, se desvelan compuestos inhibidores de quinasa, tales como compuestos inhibidores de la proteína quinasa 1 que interactúa con el receptor (RIP1), así como composiciones farmacéuticas y combinaciones que comprenden tales compuestos inhibidores. Los compuestos, las composiciones farmacéuticas y/o las combinaciones desvelados se pueden usar para tratar o prevenir una enfermedad o afección asociada a la quinasa, en particular, una enfermedad o afección asociada a la RIP1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666462P | 2018-05-03 | 2018-05-03 | |
| PCT/US2019/030476 WO2019213447A1 (en) | 2018-05-03 | 2019-05-02 | Rip1 inhibitory compounds and methods for making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200581A true CR20200581A (es) | 2021-05-11 |
Family
ID=66530556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200581A CR20200581A (es) | 2018-05-03 | 2019-05-02 | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos |
Country Status (38)
| Country | Link |
|---|---|
| US (8) | US10815206B2 (es) |
| EP (2) | EP4248975A3 (es) |
| JP (4) | JP2021523226A (es) |
| KR (1) | KR102808215B1 (es) |
| CN (4) | CN120535514A (es) |
| AU (2) | AU2019262144B2 (es) |
| BR (1) | BR112020022420A2 (es) |
| CA (1) | CA3099037A1 (es) |
| CL (1) | CL2020002841A1 (es) |
| CO (1) | CO2020015156A2 (es) |
| CR (1) | CR20200581A (es) |
| DK (1) | DK3788044T3 (es) |
| DO (2) | DOP2020000198A (es) |
| EA (1) | EA202092580A1 (es) |
| EC (1) | ECSP20078326A (es) |
| ES (1) | ES2956087T3 (es) |
| FI (1) | FI3788044T3 (es) |
| HR (1) | HRP20231381T1 (es) |
| HU (1) | HUE063896T2 (es) |
| IL (2) | IL299784B2 (es) |
| JO (2) | JOP20200278B1 (es) |
| LT (1) | LT3788044T (es) |
| MA (1) | MA52488B1 (es) |
| MD (1) | MD3788044T2 (es) |
| MX (1) | MX2020011621A (es) |
| MY (1) | MY208132A (es) |
| PE (1) | PE20211383A1 (es) |
| PH (1) | PH12020551847A1 (es) |
| PL (1) | PL3788044T3 (es) |
| PT (1) | PT3788044T (es) |
| RS (1) | RS64736B1 (es) |
| SA (1) | SA520420468B1 (es) |
| SG (1) | SG11202010915XA (es) |
| SI (1) | SI3788044T1 (es) |
| SM (1) | SMT202300313T1 (es) |
| UA (1) | UA128369C2 (es) |
| WO (1) | WO2019213447A1 (es) |
| ZA (2) | ZA202007486B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202092580A1 (ru) * | 2018-05-03 | 2021-04-07 | Ригел Фармасьютикалз, Инк. | Соединения, ингибирующие rip1, а также способы их получения и применения |
| UA128160C2 (uk) | 2018-05-03 | 2024-04-24 | Райджел Фармасутікалс, Інк. | Сполуки, що інгібують rip1, а також способи їх одержання та застосування |
| WO2020088194A1 (zh) | 2018-11-02 | 2020-05-07 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
| CN111138448B (zh) * | 2018-11-02 | 2022-08-02 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
| US12365695B2 (en) * | 2019-08-09 | 2025-07-22 | Bisichem Co., Ltd. | Fused ring heteroaryl compounds as RIPK1 inhibitors |
| KR102793185B1 (ko) * | 2019-09-06 | 2025-04-09 | 리겔 파마슈티칼스, 인크. | Rip1 억제 화합물 및 그를 제조 및 사용하는 방법 |
| CA3149926A1 (en) | 2019-09-06 | 2021-03-11 | Yan Chen | Rip1 inhibitory compounds and methods for making and using the same |
| WO2021046515A1 (en) | 2019-09-06 | 2021-03-11 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| IL291665B2 (en) | 2019-09-27 | 2025-07-01 | Univ Texas | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| EP3861676B1 (en) | 2019-10-21 | 2025-08-06 | Google LLC | Verifiable consent for privacy protection |
| AU2020378407B2 (en) | 2019-11-07 | 2024-02-01 | Rigel Pharmaceuticals, Inc. | Heterocyclic RIP1 inhibitory compounds |
| JP2023502514A (ja) * | 2019-11-26 | 2023-01-24 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | 疾患の処置のための受容体相互作用プロテインキナーゼｉの阻害剤 |
| AU2021225921A1 (en) * | 2020-02-28 | 2022-09-22 | Board Of Regents, The University Of Texas System | Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease |
| AR121717A1 (es) * | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| TWI840311B (zh) | 2020-07-01 | 2024-04-21 | 美商雷傑製藥公司 | Rip1k抑制劑 |
| WO2022171111A1 (en) * | 2021-02-10 | 2022-08-18 | Zai Lab (Us) Llc | Heteroaryl-fused bicyclic compound as rip1-kinase inhibitors and uses thereof |
| AR125587A1 (es) | 2021-03-11 | 2023-08-02 | Rigel Pharmaceuticals Inc | Inhibidores heterocíclicos de la quinasa de rip1 |
| CN114989156B (zh) * | 2021-05-19 | 2024-07-05 | 成都贝诺科成生物科技有限公司 | 一种受体相互作用蛋白抑制剂及其制备方法和用途 |
| KR20240135076A (ko) | 2021-08-10 | 2024-09-10 | 애브비 인코포레이티드 | 니코틴아미드 ripk1 억제제 |
| CN118510774A (zh) | 2021-12-16 | 2024-08-16 | 里格尔药品股份有限公司 | Ripk1抑制剂的结晶形式 |
| WO2023138317A1 (zh) * | 2022-01-21 | 2023-07-27 | 中国科学院上海药物研究所 | 具有ripk1抑制活性的化合物、其制备方法及其用途 |
| US20250197390A1 (en) * | 2022-03-16 | 2025-06-19 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Fused heterocyclic compound, and preparation method therefor and medical use thereof |
| CN114736197B (zh) * | 2022-06-13 | 2022-09-13 | 南京医工医药技术有限公司 | 咪唑啉酮衍生物及其用途 |
| CN115353513A (zh) * | 2022-07-29 | 2022-11-18 | 中国人民解放军海军军医大学 | 一种抑制程序性细胞坏死的硫代七元环衍生物及其应用 |
| KR20260028073A (ko) | 2023-06-26 | 2026-03-03 | 일라이 릴리 앤드 캄파니 | 자가면역 및 염증성 질환을 치료하기 위한 ly3871801을 사용한 투여 요법 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
| US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
| US4738851A (en) | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
| US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
| US4882150A (en) | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
| US5521222A (en) | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| EP0431519B1 (en) | 1989-12-04 | 1994-06-15 | G.D. Searle & Co. | System for transdermal albuterol administration |
| US5077033A (en) | 1990-08-07 | 1991-12-31 | Mediventures Inc. | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide |
| ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
| US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
| DE69228827T2 (de) | 1991-12-18 | 1999-10-21 | Minnesota Mining And Mfg. Co., Saint Paul | Mehrschichtige sperrstrukturen |
| EP0553769B1 (de) | 1992-01-29 | 1996-01-03 | FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG | Ballspielschläger, insbesondere Tennisschläger |
| IL114193A (en) | 1994-06-20 | 2000-02-29 | Teva Pharma | Ophthalmic pharmaceutical compositions based on sodium alginate |
| ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
| IT1283911B1 (it) | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
| US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
| US6261547B1 (en) | 1998-04-07 | 2001-07-17 | Alcon Manufacturing, Ltd. | Gelling ophthalmic compositions containing xanthan gum |
| US6197934B1 (en) | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
| US20090099242A1 (en) | 2007-08-15 | 2009-04-16 | Cuny Gregory D | Heterocyclic inhibitors of necroptosis |
| TWI648274B (zh) * | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| US9725452B2 (en) | 2013-03-15 | 2017-08-08 | Presidents And Fellows Of Harvard College | Substituted indoles and pyrroles as RIP kinase inhibitors |
| RU2017109122A (ru) * | 2014-08-21 | 2018-09-21 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы |
| CN107207485A (zh) | 2015-02-13 | 2017-09-26 | 葛兰素史密斯克莱知识产权发展有限公司 | (S)‑5‑苄基‑N‑(5‑甲基‑4‑氧代‑2,3,4,5‑四氢苯并[b][1,4]氧氮杂环庚三烯‑3‑基)‑4H‑1,2,4‑三唑‑3‑甲酰胺的晶型 |
| TWI763630B (zh) | 2015-07-02 | 2022-05-11 | 瑞士商赫孚孟拉羅股份公司 | 雙環內醯胺及其使用方法 |
| US10426758B2 (en) | 2015-10-13 | 2019-10-01 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis |
| JP6754772B2 (ja) | 2015-10-23 | 2020-09-16 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2017109724A1 (en) | 2015-12-21 | 2017-06-29 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| MA44007A (fr) * | 2016-02-05 | 2018-12-19 | Denali Therapeutics Inc | Inhibiteurs du récepteur interagissant avec protéine kinase 1 |
| EP3526219B1 (en) * | 2016-10-17 | 2021-12-15 | F. Hoffmann-La Roche AG | Bicyclic pyridone lactams and methods of use thereof |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| EP3585782A1 (en) * | 2017-02-27 | 2020-01-01 | GlaxoSmithKline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| EA202092580A1 (ru) | 2018-05-03 | 2021-04-07 | Ригел Фармасьютикалз, Инк. | Соединения, ингибирующие rip1, а также способы их получения и применения |
| UA128160C2 (uk) * | 2018-05-03 | 2024-04-24 | Райджел Фармасутікалс, Інк. | Сполуки, що інгібують rip1, а також способи їх одержання та застосування |
| EP3816163A4 (en) | 2018-06-26 | 2022-04-13 | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences | CELL NECROSIS INHIBITORS, METHOD OF MANUFACTURE THEREOF AND USE THEREOF |
| CN111138448B (zh) | 2018-11-02 | 2022-08-02 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
| WO2020088194A1 (zh) | 2018-11-02 | 2020-05-07 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
| CA3149926A1 (en) | 2019-09-06 | 2021-03-11 | Yan Chen | Rip1 inhibitory compounds and methods for making and using the same |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
-
2019
- 2019-05-02 EA EA202092580A patent/EA202092580A1/ru unknown
- 2019-05-02 IL IL299784A patent/IL299784B2/en unknown
- 2019-05-02 CN CN202510681112.6A patent/CN120535514A/zh active Pending
- 2019-05-02 MA MA52488A patent/MA52488B1/fr unknown
- 2019-05-02 AU AU2019262144A patent/AU2019262144B2/en active Active
- 2019-05-02 PL PL19724048.4T patent/PL3788044T3/pl unknown
- 2019-05-02 BR BR112020022420-0A patent/BR112020022420A2/pt active Search and Examination
- 2019-05-02 CN CN201980045101.1A patent/CN112368278B/zh active Active
- 2019-05-02 KR KR1020207034549A patent/KR102808215B1/ko active Active
- 2019-05-02 LT LTEPPCT/US2019/030476T patent/LT3788044T/lt unknown
- 2019-05-02 CN CN202510681108.XA patent/CN120535512A/zh active Pending
- 2019-05-02 MX MX2020011621A patent/MX2020011621A/es unknown
- 2019-05-02 DK DK19724048.4T patent/DK3788044T3/da active
- 2019-05-02 MD MDE20210212T patent/MD3788044T2/ro unknown
- 2019-05-02 CA CA3099037A patent/CA3099037A1/en active Pending
- 2019-05-02 EP EP23181764.4A patent/EP4248975A3/en active Pending
- 2019-05-02 UA UAA202007531A patent/UA128369C2/uk unknown
- 2019-05-02 RS RS20230982A patent/RS64736B1/sr unknown
- 2019-05-02 PE PE2020001784A patent/PE20211383A1/es unknown
- 2019-05-02 FI FIEP19724048.4T patent/FI3788044T3/fi active
- 2019-05-02 HU HUE19724048A patent/HUE063896T2/hu unknown
- 2019-05-02 WO PCT/US2019/030476 patent/WO2019213447A1/en not_active Ceased
- 2019-05-02 JP JP2021510284A patent/JP2021523226A/ja not_active Withdrawn
- 2019-05-02 SG SG11202010915XA patent/SG11202010915XA/en unknown
- 2019-05-02 SM SM20230313T patent/SMT202300313T1/it unknown
- 2019-05-02 HR HRP20231381TT patent/HRP20231381T1/hr unknown
- 2019-05-02 SI SI201930598T patent/SI3788044T1/sl unknown
- 2019-05-02 ES ES19724048T patent/ES2956087T3/es active Active
- 2019-05-02 US US16/402,111 patent/US10815206B2/en active Active
- 2019-05-02 CN CN202510681110.7A patent/CN120535513A/zh active Pending
- 2019-05-02 CR CR20200581A patent/CR20200581A/es unknown
- 2019-05-02 MY MYPI2020005721A patent/MY208132A/en unknown
- 2019-05-02 IL IL278417A patent/IL278417B2/en unknown
- 2019-05-02 PT PT197240484T patent/PT3788044T/pt unknown
- 2019-05-02 EP EP19724048.4A patent/EP3788044B1/en active Active
-
2020
- 2020-09-16 US US17/023,138 patent/US11377428B2/en active Active
- 2020-09-16 US US17/023,127 patent/US11332451B2/en active Active
- 2020-09-16 US US17/023,149 patent/US11370765B2/en active Active
- 2020-09-16 US US17/023,136 patent/US11370764B2/en active Active
- 2020-10-16 US US17/072,862 patent/US11472782B2/en active Active
- 2020-11-02 CL CL2020002841A patent/CL2020002841A1/es unknown
- 2020-11-02 DO DO2020000198A patent/DOP2020000198A/es unknown
- 2020-11-03 JO JOJO/P/2020/0278A patent/JOP20200278B1/ar active
- 2020-11-03 PH PH12020551847A patent/PH12020551847A1/en unknown
- 2020-11-03 SA SA520420468A patent/SA520420468B1/ar unknown
- 2020-12-01 ZA ZA2020/07486A patent/ZA202007486B/en unknown
- 2020-12-01 CO CONC2020/0015156A patent/CO2020015156A2/es unknown
- 2020-12-03 EC ECSENADI202078326A patent/ECSP20078326A/es unknown
-
2021
- 2021-11-04 ZA ZA2021/08603A patent/ZA202108603B/en unknown
-
2022
- 2022-08-10 JP JP2022128202A patent/JP7187729B2/ja active Active
- 2022-09-07 US US17/939,020 patent/US12116354B2/en active Active
- 2022-11-30 JP JP2022191875A patent/JP7367169B2/ja active Active
-
2023
- 2023-08-25 DO DO2023000169A patent/DOP2023000169A/es unknown
- 2023-10-11 JP JP2023175695A patent/JP7735368B2/ja active Active
- 2023-10-26 AU AU2023254980A patent/AU2023254980B2/en active Active
- 2023-10-26 JO JOJO/P/2023/0272A patent/JOP20230272A1/ar unknown
-
2024
- 2024-09-19 US US18/890,094 patent/US20250034100A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2023000169A (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
| DOP2022000051A (es) | Compuestos inhibidores de rip1 y métodos para hacer y utilizar los mismos | |
| CO2020015153A2 (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
| DOP2022000215A (es) | Inhibidores de rip1k | |
| DOP2022000042A (es) | Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos | |
| MX2022005509A (es) | Compuestos inhibidores de rip1 heterociclicos. | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| CO2023000051A2 (es) | Inhibidores de rip1k | |
| PY2055444A (es) | Composiciones nematicidas | |
| AR120412A1 (es) | Compuestos heterocíclicos inhibidores de rip1 | |
| CO2023012077A2 (es) | Inhibidores heterocíclicos de la cinasa rip1 |